Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice
Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice
复制标题
DOI：
10.1038/sj.leu.2404147
复制
发表时间：
2006-05-01
期刊：
影响因子：
11.4
通讯作者：
Dilber, MS
中科院分区：
文献类型：
--
作者：
Guimaraes, F;Guven, H;Dilber, MS
近年来，使用自然杀伤（NK）细胞治疗人类恶性血液病的可能性有所增加。促成这一点的一个因素是引入了用于离体产生临床级NK细胞的富集群体的新方法。本研究的目的是在重度联合免疫缺陷病（SCID）-米色小鼠中评价人离体扩增的临床级NK细胞对K562白血病细胞的安全性和有效性。将经辐照的SCID-米色小鼠静脉内（i. v.）K562白血病细胞在白血病细胞注射后，向小鼠注射离体扩增的人NK细胞。在体内跟踪NK细胞，并监测小鼠的白血病存活率。这些离体扩增的临床级NK细胞的施用是安全的，并且防止了白血病的发展。总之，这些结果意味着这种NK细胞制剂在人类血液恶性肿瘤和可能的其他形式的癌症的治疗试验中使用的可能性。
The possibility of using natural killer (NK) cells in treatment of human hematological malignancies has increased in recent years. One factor contributing to this is the introduction of new methods for ex vivo generation of enriched populations of clinical grade NK cells. The objective of the present study was to evaluate the safety and efficacy of human ex vivo expanded clinical grade NK cells against K562 leukemia cells in severe combined immunodeficiency disease (SCID)-beige mice. Irradiated SCID-beige mice were injected intravenously (i.v.) with K562 leukemia cells. Following leukemia cell injection, mice were injected with ex vivo expanded human NK cells. NK cells were followed in vivo and mice monitored for survival from leukemia. Administration of these ex vivo expanded clinical grade NK cells was safe and prevented leukemia development. In conclusion, these results imply possibilities for the use of this NK cell preparation in treatment trials of human hematological malignancies and possibly other forms of cancer.